The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?

Answers are grounded in this paper and cite their sources.

• What was the primary endpoint, and how big was the effect?
• What are the main limitations?
• How does this compare with earlier trials?